Figure 2.

Key efficacy endpoints over time. Error bars represent 95% CIs. ^aGM of the ratio of the 24-hour UPCR values at each time point over the baseline value for each treatment group (values <1 indicate an improvement). ^bGMR of the relative improvement in 24-hour UPCR for anifrolumab groups vs placebo groups, where GMR <1 favours anifrolumab. A p≤0.05 for the combined anifrolumab vs placebo group was deemed significant. All other p values presented are nominal. ^cPatients from France and Italy (n=13) were excluded from the analysis (see online supplemental material). ^dProbability of obtaining a sustained CRR_0.5 was analysed post hoc using a Cox regression model controlling for stratification factors. BR, basic regimen; CRR, complete renal response; CRR_0.5, CRR with UPCR ≤0.5 mg/mg; GM, geometric mean; GMR, geometric mean ratio; IR, intensified regimen; UPCR, urine protein–creatinine ratio.